Mengfei Ye1,2, Kanghui Du1, Jingying Zhou1, Quanqian Zhou1, Mengna Shou3, Baiqi Hu1, Panruo Jiang1, Nan Dong1, Luying He1, Shenglin Liang2, Chaoyang Yu1, Jian Zhang1, Zhinan Ding1,4, Zheng Liu1,4. 1. Department of Clinical Medicine, Medical College of Shaoxing University, Shaoxing, Zhejiang, China. 2. Department of Psychiatry, Shaoxing Seventh People's Hospital, Shaoxing, Zhejiang, China. 3. Department of Gynecology and Obstetrics, Shaoxing Women and Children's Hospital, Shaoxing, Zhejiang, China. 4. Laboratory of Forensic Toxicology, Judicial Identification Center of Shaoxing University, Shaoxing, Zhejiang, China.
Abstract
OBJECTIVE: The aim of this study was to examine the effect of cognitive behavior therapy (CBT) on quality of life (QOL) and psychological health of breast cancer survivors and patients. METHODS: A total of 1289 references were examined from an overall literature search in PubMed, Embase, CINAHL, and the Cochrane Database of Systematic Reviews. Randomized controlled trials assessing the efficacy of CBT compared with a range of comparators in cancer survivors. We assessed the effect of CBT by using the standardized mean difference as effect size. RESULTS: Among 1289 abstracts and 292 full-text articles reviewed, 10 studies were included. At the posttreatment period, the pooled effect size for CBT on QOL was 0.57 (95% CI, 0.44 to 0.69; P < .001), on depression was -1.11 (95% CI, -1.28 to -0.94; P < .001), on stress was -0.40 (95% CI, -0.53 to -0.26; P < .001), on anxiety was -1.10 (95% CI, -1.27 to -0.93; P < .001), and on hyperarousal cluster of symptoms was -0.18 (95% CI, -0.30 to -0.05; P < .001). The QOL was considered statistically medium effect sizes. The depression and anxiety were considered statistically large effect sizes. CONCLUSIONS: Cognitive behavior therapy is an effective therapy for psychological symptoms of cancer survivors and patients, with meaningfully clinical effect sizes. These findings suggested that CBT should be used as the intervention for breast cancer survivors and patients when possible.
OBJECTIVE: The aim of this study was to examine the effect of cognitive behavior therapy (CBT) on quality of life (QOL) and psychological health of breast cancer survivors and patients. METHODS: A total of 1289 references were examined from an overall literature search in PubMed, Embase, CINAHL, and the Cochrane Database of Systematic Reviews. Randomized controlled trials assessing the efficacy of CBT compared with a range of comparators in cancer survivors. We assessed the effect of CBT by using the standardized mean difference as effect size. RESULTS: Among 1289 abstracts and 292 full-text articles reviewed, 10 studies were included. At the posttreatment period, the pooled effect size for CBT on QOL was 0.57 (95% CI, 0.44 to 0.69; P < .001), on depression was -1.11 (95% CI, -1.28 to -0.94; P < .001), on stress was -0.40 (95% CI, -0.53 to -0.26; P < .001), on anxiety was -1.10 (95% CI, -1.27 to -0.93; P < .001), and on hyperarousal cluster of symptoms was -0.18 (95% CI, -0.30 to -0.05; P < .001). The QOL was considered statistically medium effect sizes. The depression and anxiety were considered statistically large effect sizes. CONCLUSIONS:Cognitive behavior therapy is an effective therapy for psychological symptoms of cancer survivors and patients, with meaningfully clinical effect sizes. These findings suggested that CBT should be used as the intervention for breast cancer survivors and patients when possible.
Authors: Lata K McGinn; Anna Van Meter; Ian Kronish; Jessica Gashin; Karen Burns; Natalie Kil; Thomas G McGinn Journal: Cognit Ther Res Date: 2019-02-12
Authors: Marieke van Leeuwen; Jacobien M Kieffer; Teresa E Young; Maria Antonietta Annunziata; Volker Arndt; Juan Ignacio Arraras; Didier Autran; Hira Bani Hani; Manas Chakrabarti; Olivier Chinot; Juhee Cho; Rene Aloisio da Costa Vieira; Anne-Sophie Darlington; Philip R Debruyne; Linda Dirven; Daniela Doege; Yannick Eller; Martin Eichler; Nanna Fridriksdottir; Ioannis Gioulbasanis; Eva Hammerlid; Mieke van Hemelrijck; Silke Hermann; Olga Husson; Michael Jefford; Christoffer Johansen; Trille Kristina Kjaer; Meropi Kontogianni; Pernilla Lagergren; Emma Lidington; Karolina Lisy; Ofir Morag; Andy Nordin; Amal S H Al Omari; Andrea Pace; Silvia De Padova; Duska Petranovia; Monica Pinto; John Ramage; Elke Rammant; Jaap Reijneveld; Samantha Serpentini; Sam Sodergren; Vassilios Vassiliou; Irma Verdonck-de Leeuw; Ingvild Vistad; Teresa Young; Neil K Aaronson; Lonneke V van de Poll-Franse Journal: J Cancer Surviv Date: 2022-01-27 Impact factor: 4.442
Authors: Anao Zhang; Kaipeng Wang; Kate Blumenstein; Anna Brose; Chris Kemp; Dalton Meister; Phyllis Solomon Journal: Support Care Cancer Date: 2022-08-30 Impact factor: 3.359
Authors: Godfred O Antwi; David K Lohrmann; Wasantha Jayawardene; Angela Chow; Cecilia S Obeng; Aaron M Sayegh Journal: J Cancer Educ Date: 2022-06 Impact factor: 1.771
Authors: Kelly E Rentscher; Judith E Carroll; Mark B Juckett; Christopher L Coe; Aimee T Broman; Paul J Rathouz; Peiman Hematti; Erin S Costanzo Journal: J Natl Cancer Inst Date: 2021-10-01 Impact factor: 13.506
Authors: Kristin L Szuhany; Matteo Malgaroli; Gabriella Riley; Carly D Miron; Rebecca Suzuki; Jae Hyung Park; Jane Rosenthal; Abraham Chachoua; Marleen Meyers; Naomi M Simon Journal: Breast Cancer Res Treat Date: 2021-06-07 Impact factor: 4.624
Authors: Maria Charalampopoulou; Flora Bacopoulou; Konstantinos N Syrigos; Evaggelos Filopoulos; George P Chrousos; Christina Darviri Journal: Breast Date: 2019-12-20 Impact factor: 4.380